TOP HEADLINES

Featured Story

Zydus Cadila said to be buying Claris' sterile injectables biz as landscape morphs

Earlier this week, Endo said it would lay out $8 billion for Par Pharmaceuticals to get its hands on that company's sterile injectables biz. Now another deal is brewing in India forClaris Lifesciences operations in that part of the market.

Apotex recalling generic Zyprexa because the antipsychotic may be too weak

Canadian generics maker Apotex is recalling more than 35,000 bottles of generic Zyprexa, an antipsychotic, that were manufactured at a plant in Toronto that was recently nicked by the FDA for a number of issues.

Fund grows to $200M for victims of meningitis outbreak tied to compounder

A fund for victims of a fungal meningitis outbreak that sprung from contaminated drugs sold by the now-defunct New England Compounding Center has reached $200 million, twice what was initially expected.

Hospira recalls solution marked as heparin

Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.

Janssen gets Rutgers' help in move to continuous manufacturing

In a virtuous cycle, Johnson & Johnson is kicking in some more funding for continous manufacturing research by Rutgers University, whose engineers are helping J&J's Janssen unit transition some products to the new technology at a plant in Puerto Rico.

MORE NEWS

From Our Sister Sites

FierceBiotech

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a...

FiercePharma

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.